On 4/12/2017, Shares of Synthesis Energy Systems, Inc. (NASDAQ:SYMX) closed at $0.8616 in last trading day. After noting the initial trading entry at $0.8600, it reached to a day’s high of $0.9000 and moved to a day’s low of $0.7801. The recent daily volume was 595.17 thousand as contrast to it’s an average volume of 96.81 thousand.
The last close of the Synthesis Energy Systems, Inc. stock reflects that it traded up +0.4781% from its 50-day moving average of $0.8575. The stock traded below -6.5612% to its 200-day MA of $0.9221. Furthermore, it moved lower -40.5793% from its 52-week high of $1.4500 and +22.1954% up from $0.7051, which is 52-week low of the stock.
During the last month, Synthesis Energy Systems, Inc.’s (SYMX) has changed 3.81% and performed -23.75% over the last 6 months. The mean rating score for this stock is at 2.00. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 5.03% in recent month and observed Weekly Volatility of 6.00%.
Synthesis Energy Systems, Inc., an energy and gasification technology company, together with its subsidiaries, provides proprietary gasification technology systems and solutions to the energy and chemical industries worldwide. The company offers U-GAS fluidized bed gasification technology that produces synthesis gas from various energy resources, including coal, biomass, municipal wastes, refuse derived fuels, and petroleum coke. Its synthesis gas can be converted into a range of energy and chemical products, such as industrial fuel gas, substitute natural gas, electricity, hydrogen, ammonia, and methanol. The company also has rights to sublicense U-GAS systems to third parties for coal, and coal and biomass mixtures, as well as for biomass projects. In addition, it offers XL3000 gasification system for use in synthesis gas projects, such as electricity, steelmaking, industrial chemicals, fertilizers, substitute natural gas, and transportation fuels. Synthesis Energy Systems, Inc. was founded in 2003 and is headquartered in Houston, Texas.
Arrowhead Research Corporation (NASDAQ:ARWR) finalized the last transaction at value of $1.65, with a daily change of -0.60% or -0.01 points. The company maintained volume of 558.33 thousand shares. In past trading day, the stock hit the maximum price of $1.68 and touched to minimum value of $1.64. It has a market cap of $ 123.04M.
As of last trade close, the stock is trading downside -79.93% from its one year high of $8.22 and moved +37.50% upward from $1.20, which is one year low of the stock.
The stock traded below -16.46% from its 50-day moving average of $1.98. Furthermore, the stock moved -48.32% to its 200-day MA of $ 3.19.
Arrowhead Pharmaceuticals, Inc.’s (ARWR) moved with shift of -0.60% in the past week. Over the last three months, the shares of the company have changed -26.01% and performed -76.26% over the last six months. The stock currently has Monthly Volatility of 5.80% and Weekly Volatility of 3.77%.
Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.